diabetes
Conditions
Interventions
The treatment group :Standard treatment + Composite Danshen Pill 10 / times three times a day orally
Control Group :Standard therapy plus aspirin enteric-coated tablets 100mg / time orally once daily
Sponsors
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. 1999 WHO criteria for diagnosis of type 2 diabetes; 2. Age range 40 to 75 years; 3. Glycated hemoglobin> 6% but =40 years of age, there is involvement of coronary, cerebrovascular or peripheral vascular system of atherosclerosis-related clinical events; The Standard of multiple risk factors: age (men >=55 years, women >=60 years), at least one of the following additional risk factors: dyslipidemia, hypertension, or active smoking.
Exclusion criteria
Exclusion criteria: 1. The patients who are hypersensitive to the components of the CSDP or aspirin; 2. The patients who have diabetic ketoacidosis and severe cardiovascular and cerebrovascular diseases and other major adverse events occurred within six months; 3. Severe liver and kidney disease; 4. The patients who have active peptic ulcer or gastrointestinal bleeding; 5. Mental disorders or cognitive disorders; 6. Pregnant and lactating women, women of childbearing age who do not agree to take contraceptive measures during the trial; 7. The patients who are participating in other clinical trials; 8. The patients who can not take medication on time; 9. The patients that researchers believe not suitable for clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine albumin;urine creatinine;Carotid ultrasound; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiovascular and cerebrovascular events; | — |
Countries
China
Contacts
Public ContactLU Hao
Outcome results
None listed